Skip to main content
Clinical Trials/NCT03944161
NCT03944161
Terminated
Not Applicable

Effectiveness and Cost-Effectiveness Study of Medical Nutrition in Malnourished Patients in Spain

Asociación Española de Fabricantes y Distribuidores de Productos de Nutrición Enteral7 sites in 1 country380 target enrollmentNovember 20, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Malnutrition
Sponsor
Asociación Española de Fabricantes y Distribuidores de Productos de Nutrición Enteral
Enrollment
380
Locations
7
Primary Endpoint
Body mass index
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

The present study aims to evaluate the use of oral nutritional supplementation in persons with some clinical conditions presenting malnutrition in some extent.

Detailed Description

COSNUT pretends to assess the cost-effectiveness and cost-utility of oral nutritional supplementation (ONS) in persons with malnutrition and other clinical conditions. The effectiveness will be evaluated by comparing the intervention group having ONS vs a control group only with nutrition advice. The effectiveness and resource use will be collected using quality of life assessment tools, body mass index, change in malnutrition state, number of hospital admissions, medical visits... Unitary costs for Spain will be extracted from databases and official publications and will be applied to the number of resources used in order to calculate the costs in each of the groups. Finally, the incremental cost-effectiveness ratio will be estimated and presented.

Registry
clinicaltrials.gov
Start Date
November 20, 2019
End Date
May 11, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Asociación Española de Fabricantes y Distribuidores de Productos de Nutrición Enteral
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Nutritional status B or C (GSA criteria)
  • Presenting one of the following conditions:
  • Cancer patient after surgery, radiotherapy on antineoplastic treatment.
  • Hip fracture
  • Heart failure NYHA (New York Heart Association) III-IV.
  • Breathing failure GOLD 3 o 4: FEV1 (forced expiratory volume at one second ) \<50%.
  • Renal failure GFR\<30 (glomerular filtration rate )
  • Participants agreeing the informed consent

Exclusion Criteria

  • Cancer patients: esophagus, stomach, pancreas and Head and neck
  • Hospital admitted patients at the time of recruitment
  • Life expectancy below 3 months
  • Pregnant or nursing women
  • Use of oral nutritional supplements in the three months prior the enrolment
  • History of allergy to oral nutritional supplements
  • Diabetes mellitus type
  • Participation in any other study at the time of enrolment
  • Cognitive limitations to participate in the study

Outcomes

Primary Outcomes

Body mass index

Time Frame: 6 months

Index for relating weight to height. Abbreviated BMI. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared

Strength

Time Frame: from baseline-6 months

hand grip strength test

Strength and endurance

Time Frame: from baseline-6 months

30-second Chair Stand Test

Change in nutritional status

Time Frame: from basal-6 months

Change in the Global Subjective Assessment (this scale categorize participants into A, B or C being A the best nutritional status and C the worst.)

Functional status

Time Frame: from baseline-6 months

Katz index (this index categorize in one of 7 categories: A,B,C,D,E,F,G from independent for all functions (A) to dependent for all functions (G))

Number of Hospital admittance

Time Frame: at 30 days

Number of admittance from randomization

Number of Hospital admittances

Time Frame: from randomization to 6 months

Number of admittance from randomization

Number of participants Diagnosed of malnutrition

Time Frame: from baseline-6 months

Diagnosis of malnutrition using GLIM criteria

Health related quality of life

Time Frame: from baseline-6 months

EuroQoL 5 dimensions and 5 levels(EQ5D5L) (scale between 0 which is the death and 1 which is the best health status)

Number of Medical doctor visits

Time Frame: from randomization to 6 months

Visits to any outpatient medical office

Secondary Outcomes

  • Number of deaths(from randomization to 6 months)
  • Number of secondary effects related to the intervention(from randomization to 6 months)
  • Number of Infections(at 6 months)

Study Sites (7)

Loading locations...

Similar Trials